Aduro Biotech, Inc. has entered a clinical collaboration with Merck to investigate the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the treatment of gastric cancer.   “CRS-207 has demonstrated the ability to induce an anti-tumor immune response in clinical trials in other tumor types that over express the tumor antigen, mesothelin,” said Dirk G. Brockstedt, Ph.D., executive vice president...